Richard L. Bowen, M.D., founder of OTB Research and co-founder of Voyager Pharmaceutical Corporation. Dr. Bowen researches endocrinological mechanisms of aging and has initiated two phase II clinical trials to evaluate the efficacy of gonadotropin releasing hormone analogue leuprolide acetate for the treatment of Alzheimer's disease. ALADDIN I (Anti-gonadotropin Leuprolide in Alzheimer's Disease Drug INvestigation) is a 90-patient women's study that is fully enrolled and ALADDIN II is a similar study that is currently enrolling 105 men. Following the success of the ALADDIN I trial, a Phase III clinical trial recruiting 550 patients in the USA and another 550 patients predominantly in Europe has commenced. A graduate of the University of South Carolina and the Medical University of South Carolina, Dr. Bowen received his board certification after completing a three-year residency in family medicine at Spartanburg Regional Medical Center in 1988.

Ralph N. Martins, Ph.D. and Giuseppe Verdile, Ph.D., Edith Cowan University. Long-term collaborators on the role of hormones in Alzheimer's disease.

George Perry, Ph.D., Dean of College of Sciences, University of Texas at San Antonio, Texas, and Sandi Siedlek, M.S., Case Western Reserve University. Collaborator on oxidative mechanisms of protein modification and antioxidant treatments for neurodegenerative diseases.

Mark Smith, Ph.D., and Gemma Casadesus, Ph.D., Case Western Reserve University. Collaborators on cell cycle related mechanisms of Alzheimer's disease.